Search icon
Learn, Analyse & Invest
only with
Orca logoArrow icon
+91
Download Orca
orca play storeorca apple store
To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Solara Active Pharma Sciences Ltd.

Solara Active Pharma

0.00

0.00 (0.00)%

NSE

BSE

EX-DatePurpose
06 05 2021 Dividend & Audited Results
04 08 2021 Quarterly Results
11 11 2021 Quarterly Results
09 02 2022 Quarterly Results
29 04 2022 Dividend & Audited Results
04 08 2022 Quarterly Results
09 11 2022 Quarterly Results
25 01 2023 Quarterly Results
12 05 2023 Audited Results
05 07 2023 Right Issue of Equity Shares
11 08 2023 Quarterly Results
14 08 2023 Quarterly Results (Revised)
14 11 2023 Quarterly Results
14 02 2024 Quarterly Results
21 10 2024 Quarterly Results
24 01 2025 Quarterly Results
26 03 2025 Inter alia, to consider and approve :- a) To consider and approve, a proposal of making First Call on 1,19,98,755 partly paid-up Equity Shares, having a face value of Rs.10/- each (Rs.3.50/- paid-up) issued by the Company on rights basis in accordance with the Letter of Offer dated May 09, 2024. b) Any other matters, which may be incidental and ancillary to making aforesaid first call.
02 04 2025 Inter-alia, to consider and approve:- (1) the First Call money Notice, on the partly paid Equity Shares issued on Rights basis which is to be sent to the eligible Shareholders
15 05 2025 Audited Results
25 07 2025 Quarterly Results
05 11 2025 Quarterly Results
06 02 2026 Quarterly Results

News

19-NOV-2025

USFDA completes inspection at Solara Active Pharma Sciences’ Mangalore facility

The Agency has issued an EIR on November 18, 2025 and determined that the inspection classification of the facility is VAI and concluded this inspection as closed

12:50 PM
10-MAY-2025

USFDA concludes inspection at Solara’s Ambernath facility

The inspection established that the site is in an ‘Acceptable State of Compliance’ with Zero Form 483 inspectional observations from USFDA

04:54 PM
30-APR-2025

Solara Active Pharma Sciences incorporates wholly-owned subsidiary

The company has incorporated wholly-owned subsidiary on April 29, 2025

09:19 AM
26-MAR-2024

Solara Active Pharma Sciences gets nod to sell 100% stake in SeQuent Penems

The board of directors of the company at its meeting held on March 25, 2024 approved the same

09:49 AM
15-NOV-2023

Solara Active Pharma Sciences gets nod to sell land and building of Sequent Penems

The Board of Directors of the Company at its Meeting held on November 14, 2023 has inter-alia, considered and approved the same

09:19 AM
07-AUG-2023

USFDA concludes inspection at Solara Active Pharma Sciences’ Cuddalore facility

The inspection established that the facility is in an ‘Acceptable State of Compliance’ with Zero Form 483 inspectional observations from the Agency

09:24 AM
13-FEB-2023

Solara’s Cuddalore facility completes EU GMP Inspection

At the end of the inspection, it is concluded that the Quality Systems followed at Cuddalore site is Compliant to the EU GMP Standards

05:54 PM
30-JAN-2023

USFDA conducts inspection at Solara Active Pharma Sciences’ Visakhapatnam API manufacturing facility

The inspection established that the site is in an Acceptable State of Compliance with Zero Form 483 inspectional observations

11:00 AM
27-JAN-2023

WHO completes PQ inspection at Solara Active Pharma Sciences’ Tamil Nadu facility

The Cuddalore API site is a multi-product facility, caters wide range of APIs to various Regulated Markets across the globe

04:00 PM
01-NOV-2022

Solara gets CEP approval to manufacture Ibuprofen from Vishakhapatnam Facility

Solara also expects series of other international regulatory approvals for its Vizag facility, including USFDA

12:21 PM
Enrich money logo